TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA)...
Hence then, the article about tuhura biosciences receives fda study may proceed notice and ind clearance for the evaluation of its tbs 2025 vista inhibiting antibody in molecularly defined subsets of aml and other blood related cancers was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers )
Also on site :
- Walmart’s ‘Vintage-Style’ $15 Cordless Milk Glass Lamp Has All the Retro Charm of an Antique Store Find
- The Trump Family’s Ireland Trip: From a Bathroom Mirror Selfie with the President to Twinning with Don Jr.
- ‘The Last Photograph’ Review: DC’s Zack Snyder Comes Back Down To Earth With A Violent But Surprisingly Human Action Drama – Toronto Film Festival